2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

neutralizing antibody

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

3

Peptides

49

Inhibitory Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9917
    Tocilizumab
    Maximum Cited Publications
    24 Publications Verification

    Anti-Human IL6R, Humanized antibody

    		 Interleukin Related Inflammation/Immunology Cancer
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
    Tocilizumab
  • HY-P99275
    Patritumab
    1 Publications Verification

    Human Anti-ERBB3 Recombinant antibody

    		 EGFR Akt ERK PARP Survivin Cancer
    Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
    Patritumab
  • HY-P9945
    Mepolizumab

    SB 240563

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab
  • HY-P9945A
    Mepolizumab (anti-IL5)

    		Interleukin Related Inflammation/Immunology
    Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
    Mepolizumab (anti-IL5)
  • HY-122907
    JNJ4796

    		Influenza Virus Infection
    JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs) .
    JNJ4796
  • HY-P99604
    Cilgavimab

    AZD-1061; COV2-2130

    		 SARS-CoV Infection
    Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
    Cilgavimab
  • HY-P99937
    Elipovimab

    		HIV Infection
    Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells
    Elipovimab
  • HY-P99710
    Lomtegovimab

    BI 767551; DZIF-10c

    		 SARS-CoV Infection
    Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
    Lomtegovimab
  • HY-P4020
    2F5 epitope

    		HIV Others
    2F5 epitope, a peptide gp41 (659-671), comprises the entire epitope for one of the three known antibodies capable of neutralizing a broad spectrum of primary HIV-1 isolates and is the only such epitope that is sequential. 2F5 epitope is recognized by broadly neutralizing antibodies 2F5 .
    2F5 epitope
  • HY-153235
    COVID-19 Spike Protein mRNA-LNP

    		SARS-CoV Liposome Infection
    COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein , suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 Spike Protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 Spike Protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .
    COVID-19 Spike Protein mRNA-LNP
  • HY-P99347
    Etesevimab

    CB 6; JS016

    		 SARS-CoV Angiotensin-converting Enzyme (ACE) Infection
    Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .
    Etesevimab
  • HY-P99305
    Metelimumab
    2 Publications Verification

    CAT-192; Anti-TGFB1 Recombinant antibody

    		 TGF-β Receptor Inflammation/Immunology
    Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .
    Metelimumab
  • HY-147392
    CXCR2 antagonist 8

    		CXCR Metabolic Disease
    CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist. CXCR2 antagonist 8 can be used for insulin resistance research .
    CXCR2 antagonist 8
  • HY-D0871
    CHES

    N-Cyclohexyltaurine

    		 Biochemical Assay Reagents Others Cancer
    CHES (N-Cyclohexyltaurine) is a zwitterionic buffer. CHES can bind to hemagglutinin (HA) emulating with sialic acid (SA) and receptor binding site (RBS)-targeting broadly neutralizing antibodies .
    CHES
  • HY-P99703
    Libivirumab

    17.1.41

    		 HBV Infection
    Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
    Libivirumab
  • HY-P99307
    Namilumab

    AMG-203; Anti-Human CSF2 Recombinant antibody

    		 c-Fms Inflammation/Immunology
    Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
    Namilumab
  • HY-108739
    Idarucizumab

    BI 655075

    		 Thrombin Others Cardiovascular Disease
    Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
    Idarucizumab
  • HY-P99375
    Narnatumab

    IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference antibody (narnatumab)

    		 c-Met/HGFR Others Cancer
    Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
    Narnatumab
  • HY-P99947
    Rimteravimab

    XVR011

    		 SARS-CoV Infection
    Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
    Rimteravimab
  • HY-P99889
    Romlusevimab

    BRII-198

    		 SARS-CoV Infection
    Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
    Romlusevimab
  • HY-P99900
    Sevirumab

    MSL-109

    		 CMV Infection
    Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
    Sevirumab
  • HY-P99811
    Rafivirumab

    CR57

    		 RABV Infection
    Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
    Rafivirumab
  • HY-P9804
    Anti-MERS-2E6 mAb

    MERS-2E6; MERS antibody-2E6

    		 SARS-CoV Infection
    Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
    Anti-MERS-2E6 mAb
  • HY-P9998
    Semzuvolimab

    UB421

    		 HIV Cancer
    Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
    Semzuvolimab
  • HY-P99792
    Ormutivimab

    NM57; rhRIG

    		 RABV Infection
    Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
    Ormutivimab
  • HY-P99750
    Navivumab

    CT-P23

    		 Influenza Virus Infection
    Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
    Navivumab
  • HY-P99626
    Frovocimab

    LY 3015014

    		 PCSK9 Metabolic Disease
    Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
    Frovocimab
  • HY-P99584
    Suvizumab

    KD-247

    		 HIV Infection
    Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
    Suvizumab
  • HY-P9953
    Certolizumab pegol

    Certolizumab; CDP870

    		 TNF Receptor Inflammation/Immunology Cancer
    Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
    Certolizumab pegol
  • HY-P99424
    Afasevikumab

    RG 7624; RO 5553110; NI-1401

    		 Interleukin Related Inflammation/Immunology
    Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
    Afasevikumab
  • HY-P99137
    Anti-Mouse IFNAR1 Antibody (MAR1-5A3)

    		IFNAR Inflammation/Immunology
    Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing antibody of IFNAR1. Anti-Mouse IFNAR1 Antibody (MAR1-5A3) reacts with IFNAR1 and inhibits IFNAR1 signaling in vitro and in vivo. Mouse IgG1 kappa, Isotype Control (HY-P99977) is the isotype control of Anti-Mouse IFNAR1 Antibody (MAR1-5A3) .
    Anti-Mouse IFNAR1 Antibody (MAR1-5A3)
  • HY-P99192
    Emibetuzumab

    LY2875358

    		 c-Met/HGFR Cancer
    Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
    Emibetuzumab
  • HY-P99556
    Tixagevimab

    AZD8895

    		 SARS-CoV Infection
    Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
    Tixagevimab
  • HY-P99368
    Lacnotuzumab

    MCS110; Anti-Human B7-H3

    		 c-Fms Metabolic Disease Cancer
    Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
    Lacnotuzumab
  • HY-P99103
    Bebtelovimab

    LY-3853113; LY-COV1404

    		 SARS-CoV Infection
    Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
    Bebtelovimab
  • HY-P99486
    Briakinumab

    ABT-874

    		 Interleukin Related Inflammation/Immunology
    Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
    Briakinumab
  • HY-P99756
    Nirsevimab

    MEDI8897

    		 RSV Infection
    Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
    Nirsevimab
  • HY-P99417
    Abrezekimab

    UCB4144; VR 942

    		 Interleukin Related Inflammation/Immunology
    Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
    Abrezekimab
  • HY-P99020
    Fresolimumab
    1 Publications Verification

    GC1008

    		 TGF-beta/Smad Metabolic Disease Inflammation/Immunology Cancer
    Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
    Fresolimumab
  • HY-P4042
    Hepatitis B Virus Receptor Binding Fragment

    hepatitis B peptide 4980

    		 HBV Infection Inflammation/Immunology
    Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization .
    Hepatitis B Virus Receptor Binding Fragment
  • HY-P99100
    Visugromab
    1 Publications Verification

    CTL-002

    		 PD-1/PD-L1 Cancer
    Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .
    Visugromab
  • HY-P9806
    Anti-MERS-D12 mAb

    MERS-D12; MERS antibody-D12

    		 SARS-CoV Infection
    Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
    Anti-MERS-D12 mAb
  • HY-P99395
    Talacotuzumab

    JNJ 56022473; CSL 362

    		 Interleukin Related Cancer
    Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
    Talacotuzumab
  • HY-P9949
    Reslizumab

    Sch 55700

    		 Interleukin Related Inflammation/Immunology
    Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
    Reslizumab
  • HY-P99588
    Stamulumab

    MYO-029

    		 TGF-β Receptor Metabolic Disease
    Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
    Stamulumab
  • HY-108810
    Canakinumab

    Ilaris; ACZ 885

    		 Interleukin Related Inflammation/Immunology Cancer
    Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
    Canakinumab
  • HY-P99551
    Tosatoxumab

    KBSA301; AR-301

    		 Antibiotic Infection
    Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
    Tosatoxumab
  • HY-P9924
    Ixekizumab

    LY2439821

    		 Interleukin Related Inflammation/Immunology
    Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
    Ixekizumab
  • HY-P99340
    Sotrovimab
    1 Publications Verification

    VIR 7831

    		 SARS-CoV Infection Cancer
    Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
    Sotrovimab
  • HY-P99583
    Suvratoxumab

    MEDI4893

    		 Bacterial Infection Inflammation/Immunology
    Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
    Suvratoxumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: